- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Merck's Victrelis Hepatitis C Drug Will Be Off the Market in the US
Merck this week notified the FDA that it will stop selling its Victrelis medicine in the US by the end of this year, although the drug will remain available in other countries.
Rival hepatitis C drugs from Merck and Vertex Pharmaceuticals made a big splash when they debuted in 2011, marking an advance in treatment of the liver disease and a lucrative new market segment. But now the Class of 2011 has almost sunk to the bottom, made obsolete by a newer wave of drugs, a sign of how rapidly the hepatitis C market is changing.
Merck this week notified the FDA that it will stop selling its Victrelis medicine in the US by the end of this year, although the drug will remain available in other countries. The move comes 3 months after Vertex Pharmaceuticals discontinued US sales of its own Incivek hepatitis C drug.
Read more: http://on.wsj.com/1xYmX3N
Source: Wall Street Journal
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
